Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Acelyrin's Lonigutamab Ugodotin?
Lonigutamab Ugodotin is a monoclonal antibody commercialized by Acelyrin, with a leading Phase II program in Graves' Ophthalmopathy. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Acelyrin's Lonigutamab Ugodotin?
Lonigutamab Ugodotin is a monoclonal antibody commercialized by Acelyrin, with a leading Phase II program in Graves' Ophthalmopathy. According to...